In the U.S., it is estimated that 25-30 million people, almost 10% of the population, have rare diseases. While there are approximately 7,000 rare...
At Orsini Specialty Pharmacy, we provide our patients with both the clinical and administrative support necessary to help manage the treatment of their...
Hereditary Angioedema (HAE) is a very rare and potentially life-threatening genetic condition. HAE involves recurring attacks of severe swelling...
Mucopolysaccharidosis (MPS) is a rare disease in which the body is missing or does not have enough of an enzyme needed to break down long chains of...
This past year has shone a harsh light on some of our healthcare system’s most glaring flaws, illuminating a divide too deep to be ignored. Limited...
We are honored to share the third patient story in our "All the Difference" series, where extraordinary individuals share their experiences living with...
This blog was written by Karen Murphy, Patient Assistance Liaison at Orsini Specialty Pharmacy It’s an unfortunate truth that although incredible...
This blog was written by Mike Fieri, Orsini President and CEO. "All the Difference" is an embodiment of stories from people living with life-changing...
We are honored to share the second eBook in our "All the Difference" series, where extraordinary individuals share their experiences living with rare...
Prior authorization is used by health insurance companies to determine whether they will cover a prescribed procedure, service, or medication for a...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Orsini selected as the exclusive specialty pharmacy for WAINUA (eplontersen) for adults with hereditary transthyretin-mediated amyloid polyneuropathy
Now In Stock: ADZYNMA (ADAMTS13, recombinant-krhn), for patients with cTTP
Orsini Specialty Pharmacy Selected as Distribution Partner for Adzynma (ADAMTS13, recombinant-krhn), a Newly Approved Treatment for an Ultra-Rare Blood Clotting Disorder
Orsini Specialty Pharmacy Partners with Amicus Therapeutics to Dispense New Therapy for the Treatment of Late-Onset Pompe Disease
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer